Comparison · NCT05635838-sae
Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ruxolitinib 1.5% Cream BID vs Vehicle Cream BID: serious adverse events. Trial comparisons, record NCT05635838-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05635838-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0303 | 0.00835 | 0.104 | wilson | |
| Risk in group 2 | 0.0286 | 0.00506 | 0.145 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00173 | -0.117 | 0.079 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.06 | 0.0996 | 11.3 | log | |
| Odds ratio, group 1 over group 2 | 1.06 | 0.093 | 12.1 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Ruxolitinib 1.5% Cream BID than on Vehicle Cream BID | 577 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ruxolitinib 1.5% Cream BID | Participants applied ruxolitinib 1.5% cream BID during the Double-blind, Vehicle-controlled (DBVC) Period and the Open-label Extension (OLE) Period. Participants applied ruxolitinib 1.5% cream BID for 16 weeks in the DBVC Period. Participants who completed the Week 16 assessments with no safety concerns could continue into the 16-week OLE Period. Participants who applied ruxolitinib 1.5% cream BID during the DBVC Period continued to apply ruxolitinib 1.5% cream BID for an gadditional 16 weeks in the OLE Period. Participants who applied vehicle cream BID during the DBVC Period applied ruxolitinib 1.5% cream BID for 16 weeks in the OLE Period. | 2 | 66 | EG001 |
| Group 2 | Vehicle Cream BID | Participants applied matching vehicle cream twice a day (BID) for 16 weeks in the Double-blind, Vehicle-controlled Period. | 1 | 35 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- up to Week 32 plus 30 days
Source ClinicalTrials.gov
Trial
- Title
- Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
- NCT number
- NCT05635838
- Phases
- PHASE2
- Conditions
- Hidradenitis Suppurativa
- Interventions
- Ruxolitinib cream, Vehicle cream
- Lead sponsor
- Incyte Corporation
- Results first posted
- 2024-11-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT05635838?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT05635838-sae